Detalles de la búsqueda
1.
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Nephrol Dial Transplant
; 34(7): 1115-1124, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30380116
2.
Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.
Am J Hematol
; 93(6): E154-E156, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29575100
3.
Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function.
Kidney Int Rep
; 6(2): 296-303, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33615054
4.
Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury.
Kidney Int Rep
; 5(12): 2325-2332, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33305126
5.
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
Am J Cardiol
; 122(4): 683-688, 2018 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961562
6.
Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.
PLoS One
; 12(11): e0188712, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29186198
7.
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Transplantation
; 80(9): 1204-11, 2005 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16314787
8.
The influence of Duffy blood group on renal allograft outcome in African Americans.
Transplantation
; 75(9): 1496-500, 2003 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12792503
9.
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Transplantation
; 92(3): 303-10, 2011 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21792049
10.
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Transplantation
; 87(2): 233-42, 2009 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-19155978
11.
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Transplantation
; 86(9): 1187-95, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19005398
12.
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.
Transpl Int
; 21(5): 434-40, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18194393
13.
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
Clin Transplant
; 21(3): 330-6, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17488381
14.
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
J Am Soc Nephrol
; 17(2): 581-9, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16434506
15.
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Transpl Int
; 18(1): 22-8, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15612979
16.
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.
Am J Transplant
; 4(6): 953-61, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15147430
17.
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
J Am Soc Nephrol
; 15(3): 809-17, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14978184
Resultados
1 -
17
de 17
1
Próxima >
>>